Home›Research›Compare›Cagrilintide vs GLP-1 (7-37)
Peptide Comparison
Cagrilintide vs GLP-1 (7-37)
Both are Fat Loss peptides.
Cagrilintide
AM833
Half-life: ~7 days
13 providers listed
Quick Verdict
Cagrilintide
Risk
Half-life
~7 days
GLP-1 (7-37)
Risk
Half-life
—
Side-by-Side Comparison
About Cagrilintide
Long-acting amylin analogue; acts on amylin/calcitonin receptors to prolong satiety; synergistic with semaglutide in CagriSema combination
A once-weekly long-acting amylin analogue in late-stage development. Showing impressive weight loss (~15%) in trials, especially when combined with semaglutide (CagriSema).
Research Areas
About GLP-1 (7-37)
Binds GLP-1 receptors in the pancreas, gut, and brain. Stimulates glucose-dependent insulin secretion and suppresses glucagon. Central GLP-1 receptor activation reduces food intake via hypothalamic pathways.
The active endogenous form of glucagon-like peptide-1, an incretin hormone released from intestinal L-cells after eating. The mechanistic basis for the GLP-1 receptor agonist drug class (semaglutide, liraglutide). Studied for glucose regulation and appetite suppression.
Research Areas
Find Providers
Where to source these peptides
Providers offering
Cagrilintide
13 listed
Browse directory →
Providers offering
GLP-1 (7-37)
29 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More fat loss Comparisons
Browse all peptides →Educational research tools — not medical advice.